1 |
Tsai TA, Tsai CK, Kuo KC, et al. Rational stepwise approach for Mycoplasma pneumoniae pneumonia in children[J]. J Microbiol Immunol Infect, 2021, 54(4): 557-565.
|
2 |
Esposito S, Argentiero A, Gramegna A, et al. Mycoplasma pneumoniae:a pathogen with unsolved therapeutic problems[J]. Expert Opin Pharmacother, 2021, 22(9): 1193-1202.
|
3 |
Krafft C, Christy C. Mycoplasma pneumonia in Children and adolescents[J]. Pediatr Rev, 2020, 41(1): 12-19.
|
4 |
McGonagle D, Sharif K, O′Regan A, et al. The role of cytokines including interleukin-6 in COVID-19 induced pneumonia and macrophage activation syndrome-like disease[J]. Autoimmun Rev, 2020, 19(6): 537-539.
|
5 |
Supriya R, Gao Y, Gu Y, et al. Role of Exercise intensity on Th1/Th2 immune modulations during the COVID-19 pandemic[J]. Front Immunol, 2021, 12(9): 382-386.
|
6 |
Howard F, Kwan A, Winder N, et al. Understanding immune responses to viruses-do underlying Th1/Th2 cell biases predict outcome[J]. Viruses, 2022, 14(7): 46-53.
|
7 |
中华医学会儿科学分会呼吸学组. 儿童肺炎支原体肺炎诊治专家共识(2015年版)[J]. 中华实用儿科临床杂志,2015, 30(17): 1304-1308.
|
8 |
胡亚美,江载芳. 诸福棠实用儿科学(第7版)(上下)(精)[M]. 北京:人民卫生出版社,2012: 199-201.
|
9 |
Ranzani OT, Taniguchi LU, Torres A. Severity scoring systems for pneumonia: current understanding and next steps[J]. Curr Opin Pulm Med, 2018, 24(3): 227-236.
|
10 |
Wang H, Zhao M, Liu S, et al. Efficacy and safety of reduning injection combined with azithromycin in the treatment of mycoplasma pneumonia among children: A systematic review and meta-analysis[J]. Phytomedicine, 2022, 106(42): 402-407.
|
11 |
栾海丽,张 晗,尚云晓. 儿童肺炎支原体肺炎肺泡灌洗液中T细胞亚群及细胞因子检测的意义[J]. 中国小儿急救医学,2017, 24(11): 850-854.
|
12 |
Tong L, Huang S, Zheng C, et al. Refractory Mycoplasma pneumoniae Pneumonia in Children: Early Recognition and Management[J]. J Clin Med, 2022, 11(10): 45-51.
|
13 |
黄丽林,黄冬平,鲁灵龙,等. 支气管肺泡灌洗液中几丁质酶样蛋白YKL-40对儿童难治性肺炎支原体肺炎的预测价值[J]. 中国当代儿科杂志,2021, 23(5): 471-474.
|
14 |
Patel S. Calculated decisions: PSI/PORT score: pneumonia severity index for community-acquired pneumonia[J]. Emerg Med Pract, 2021, 23(2): D2-D3.
|
15 |
Brennan M, McDonnell MJ, Duignan N, et al. The use of cough peak flow in the assessment of respiratory function in clinical practice-A narrative literature review[J]. Respir Med, 2022, 193(54): 740-745.
|
16 |
曹小彩,余增渊,王盈红,等. sB7-H3调控Th1细胞介导免疫应答对肺炎支原体肺炎患儿病情进展的影响[J]. 中华医院感染学杂志,2022, 32(21): 3321-3325.
|
17 |
常甄瑱,童仁香,陈 倩,等. 小儿消积止咳口服液辅助治疗对肺炎支原体肺炎患儿呼吸肺功能和Th1/Th2免疫应答的影响[J]. 现代生物医学进展,2022, 22(20): 3927-3930,3961.
|
18 |
顾剑华,金晓群,徐艳娜,等. 支原体肺炎伴喘息儿童肺功能、FeNO水平及Th1/Th2免疫平衡状态的变化[J]. 海南医学,2022, 33(5): 591-594.
|
19 |
黄 瑾,章家欢,饶克瑯,等. 化痰清热方联合阿奇霉素对小儿MPP痰热闭肺证气道炎症和Th1/Th2平衡的影响[J]. 湖南中医药大学学报,2021, 41(8): 1285-1289.
|
20 |
李姗姗,包 思,刘清泉. 自拟增免调肺汤对病毒性肺炎患者Th1/Th2免疫平衡及体液免疫的影响[J]. 中国中医急症,2023, 32(3): 417-420.
|
21 |
Zhao JL, Wang X, Wang YS. Relationships between Th1/Th2 cytokine profiles and chest radiographic manifestations in childhood Mycoplasma pneumoniae pneumonia[J]. Ther Clin Risk Manag, 2016, 12(3): 1683-1692.
|
22 |
Yang M, Meng F, Gao M, et al. Cytokine signatures associate with disease severity in children with Mycoplasma pneumoniae pneumonia[J]. Sci Rep, 2019, 9(1): 17853.
|
23 |
Choy EH, De Benedetti F, Takeuchi T, et al. Translating IL-6 biology into effective treatments[J]. Nat Rev Rheumatol, 2020, 16(6): 335-345.
|
24 |
辜德明,周家仍,罗 旋,等. 细胞因子IL-6、TNF-α评估小儿支原体肺炎病情进展和预后[J/CD]. 中华肺部疾病杂志(电子版), 2021, 14(4): 505-507.
|